Lityum etkileşimleri

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Amfetamin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (Amfetamin ve dekstroamfetamin etiketi, Uyarılar ve önlemler)

Table 5: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. (Amiodaron etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Belladonna ve afyon etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Butalbital, parasetamol, kafein ve kodein etiketi, İlaç etkileşimleri)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Butorfanol etiketi, Önlemler)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (Dekstroamfetamin etiketi, Uyarılar)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fentanil etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Avoid concomitant use with lithium. (Furosemid etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Hidrokodon etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Hidrokodon ve homatropin etiketi, İlaç etkileşimleri)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Hidrokodon ve ibuprofen etiketi, Önlemler)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (Hidrokodon ve klorfeniramin etiketi, İlaç etkileşimleri)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Hidrokodon ve parasetamol etiketi, Önlemler)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Hidromorfon etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Kodein etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Levorfanol etiketi, Önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Lisdeksamfetamin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Metadon etiketi, Uyarılar ve önlemler)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Metaksalon etiketi, İlaç etkileşimleri)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Metamfetamin etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Morfin etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (Oksikodon etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Oksimorfon etiketi, İlaç etkileşimleri)

For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products. (Olanzapin etiketi, Kontrendikasyonlar)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Oliseridin etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Parasetamol ve kodein etiketi, Önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Pentazosin ve nalokson etiketi, Önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Prometazin ve kodein etiketi, İlaç etkileşimleri)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Remifentanil etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Sarı kantaronun antidepresanlarla ve diğer serotonerjik ilaçlarla birlikte alınması serotonin sendromu riskini artırır. (NCCIH, St. John's Wort)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Ziprasidon etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Amiloride may be considered as a therapeutic agent for lithium-induced nephrogenic diabetes insipidus. (Lityum etiketi, Uyarılar ve önlemler)

Lithium Theophylline increases renal lithium clearance. (Aminofilin etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (Lityum etiketi, Uyarılar ve önlemler)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

Lithium: Increases in serum lithium concentrations and lithium toxicity. (Azilsartan etiketi, İlaç etkileşimleri)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium: Symptoms of lithium toxicity ( 7.6 ) (Benazepril etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (Lityum etiketi, İlaç etkileşimleri)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (Dronabinol etiketi, Uyarılar ve önlemler)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (Lityum etiketi, İlaç etkileşimleri)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (Lityum etiketi, İlaç etkileşimleri)

Monitor serum lithium levels frequently ( 7.4 ). (Enalapril etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. (Enalaprilat etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. (Fosinopril etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (İnsülin aspart etiketi, İlaç etkileşimleri)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (İnsülin degludek etiketi, İlaç etkileşimleri)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (İnsülin detemir etiketi, İlaç etkileşimleri)

Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (İnsülin glarjin etiketi, İlaç etkileşimleri)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (İnsülin lispro etiketi, İlaç etkileşimleri)

Lithium: Risk of lithium toxicity. (İrbesartan etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Kalsiyum takviyeleri bu ilaçların emilimini azaltabilir; bunları birkaç saat arayla alın. (NIH Office of Dietary Supplements, Calcium)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium: Increases in serum lithium concentrations and toxicity ( 7 ). (Kandesartan etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (Kaptopril etiketi, İlaç etkileşimleri)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (Kinapril etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (Lityum etiketi, Uyarılar ve önlemler)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (Lityum etiketi, Uyarılar ve önlemler)

Lithium: Symptoms of lithium toxicity ( 7.5 ) (Lisinopril etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (Lityum etiketi, Uyarılar ve önlemler)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

Lithium: Risk of lithium toxicity. (Losartan etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (Lityum etiketi, İlaç etkileşimleri)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. (Moeksipril etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (Nalbufin etiketi, İlaç etkileşimleri)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7.4 ). (Olmesartan etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

Lithium: Increase serum lithium levels, symptoms of lithium toxicity. (Perindopril etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Drug Interactions: Concurrent use with lithium or antithyroid drugs may potentiate the hypothyroid and goitrogenic effects of these medications. (Potasyum iyodür etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (Lityum etiketi, Uyarılar ve önlemler)

Lithium: Use with caution (7.4). (Ramipril etiketi, İlaç etkileşimleri)

Alcohol, Beta-blockers, Clonidine, and Lithium Salts Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. (Regüler insülin (insan) etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

Lithium: Increased risk of lithium toxicity. (Sakubitril ve valsartan etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. (Sodyum polistiren sülfonat etiketi, İlaç etkileşimleri)

Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. (Somon kalsitonini etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. (Telmisartan etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

May lower theophylline seizure threshold Lithium Theophylline increases renal lithium clearance. (Teofilin etiketi, İlaç etkileşimleri)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (Lityum etiketi, Uyarılar ve önlemler)

Lithium: Monitor serum lithium concentrations ( 7.1 ) (Tinidazol etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Monitor lithium levels if lithium is used with high-dose topiramate extended-release ( 7.7 ) (Topiramat etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (Trandolapril etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (Lityum etiketi, Uyarılar ve önlemler)

Lithium: Increases in serum lithium level and lithium toxicity ( 7.4 ) (Valsartan etiketi, İlaç etkileşimleri)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (Lityum etiketi, İlaç etkileşimleri)

Drugs Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (Vazopressin etiketi, İlaç etkileşimleri)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (Lityum etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (Lityum etiketi, Uyarılar ve önlemler)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (Lityum etiketi, İlaç etkileşimleri)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (Lityum etiketi, İlaç etkileşimleri)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (Lityum etiketi, İlaç etkileşimleri)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (Lityum etiketi, İlaç etkileşimleri)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Drug Interactions ( 7.1 )]. (Lityum etiketi, Uyarılar ve önlemler)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (Oksikodon ve parasetamol etiketi, İlaç etkileşimleri)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (Lityum etiketi, İlaç etkileşimleri)

Lithium Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n = 16) had no effect on the steady-state kinetics of lithium. (Valproik asit etiketi, İlaç etkileşimleri)